SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Pictured: AbbVie sign on a building/courtesy of Ad
Drug Development
AbbVie’s Rinvoq Maintains Durability in Phase II Lupus Study
The company’s blockbuster JAK inhibitor, alone or as a combination therapy, showed durable improvements in systemic lupus erythematosus disease activity at 48 weeks.
May 31, 2023
 · 
3 min read
 · 
Heather McKenzie
Pictured: AbbVie sign on a building/courtesy of Ad
FDA
AbbVie, Genmab Score FDA Nod for DLBCL as Blood Cancer Space Heats Up
With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma.
May 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: AbbVie sign on a building/courtesy of Ad
FDA
AbbVie Adds Crohn’s Disease to Rinvoq’s Growing List of Indications
Crohn’s disease is Rinvoq’s seventh approved indication and could potentially help AbbVie weather declining sales for its blockbuster biologic Humira.
May 19, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA Action Alert graphic/@Nicole Bean
Drug Development
FDA Action Alert: Krystal, Genmab/AbbVie, Pfizer and Intercept
The FDA has four events lined up this week, including a target action date for Krystal Biotech’s gene therapy for a rare skin disease and an adcomm meeting for Pfizer’s RSV vaccine candidate.
May 11, 2023
 · 
5 min read
 · 
Tristan Manalac
Pictured: AbbVie sign on a building/courtesy of Ad
Business
Humira Sales Down 25% as AbbVie Cuts Two Programs
As Humira global revenues fall 25%, AbbVie looks to Rinvoq and Skyrizi to fill in the gap. The company also announced it is cutting cystic fibrosis and Crohn’s disease candidates.
April 28, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: AbbVie sign on a building/courtesy of Ad
Drug Development
AbbVie’s Migraine Drug Scores Another Phase III Win
AbbVie shared more positive results for its migraine prevention drug, Qulipta, just three days after FDA approval to expand its label.
April 21, 2023
 · 
2 min read
 · 
Kate Goodwin
AbbVie_© AbbVie Inc. All rights reserved.
FDA
AbbVie Wins FDA Approval for New Migraine Indication
Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.
April 19, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: scientist working on machine learning mo
10 Biopharma Companies Hiring AI/ML Talent Now
To help with your job search, here are 10 biopharma companies hiring for Artificial Intelligence and Machine Learning (AI/ML) roles now.
April 17, 2023
 · 
3 min read
 · 
Rosemary Scott
Pictured: Conceptual illustration of a person stan
Drug Development
Reformulated: New Takes on Parkinson’s Disease Treatments
Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.
April 14, 2023
 · 
4 min read
 · 
Jia Jie Chen
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Drug Development
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
October 11, 2023
 · 
19 min read
BioMidwest
AbbVie Showcases Breadth and Depth of Research in Crohn’s Disease and Ulcerative Colitis at UEG Week 2023
October 10, 2023
 · 
25 min read
Deals
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
October 5, 2023
 · 
4 min read
Drug Development
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
October 4, 2023
 · 
5 min read
Business
AbbVie to Host Third-Quarter 2023 Earnings Conference Call
October 4, 2023
 · 
1 min read
Drug Development
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
September 29, 2023
 · 
14 min read
Policy
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
September 25, 2023
 · 
18 min read
Business
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
September 13, 2023
 · 
4 min read
Job Trends
AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship “Thriving Students”
September 13, 2023
 · 
4 min read
Drug Development
AbbVie’s SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn’s Disease
September 12, 2023
 · 
12 min read
Load More